Relapsed or refractory solid tumors
Drug research and approvals for relapsed or refractory solid tumors: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 51 studies of relapsed or refractory solid tumors are recruiting on ClinicalTrials.gov, and Health Canada has authorized 12 drug trials for it since 2013.
- Recruiting worldwide: 51
- Trials authorized in Canada: 12
- FDA orphan approvals: 0
- EU medicines: 0
- Evaluation of LB-208 (HTR1B Antagonist) in Adult Patients With Relapsed or Refractory Solid Tumours and LymphomaNCT07914348 · Phase 1 · Leukos Biotech S.L. · starts Aug 7, 2024
- Study of JMBI-001 in Patients With MYC-Positive Advanced CancersNCT07864701 · Phase 1 / Phase 2 · Chengdu Anticancer Bioscience, Ltd. · starts Oct 1, 2026
- HP007 Monotherapy for Relapsed or Refractory Advanced Solid TumorsNCT07800936 · Phase 1 · Parr Biotechnology (Hebei) Co., Ltd. · starts Aug 17, 2026
- A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in…NCT07779798 · Phase 1 · Crossbow Therapeutics, Inc. · starts Aug 4, 2026
- Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)NCT07744256 · Phase 1 / Phase 2 · Beijing Biotech · starts Mar 2, 2026
- ML-016 in Advanced Cancer With Lung and/or Liver InvolvementNCT07723482 · Phase 1 / Phase 2 · BrYet US, Inc. · starts Sep 25, 2026
- Evaluation of XYA02 in Patients With Advanced Solid TumorsNCT07670312 · Phase 1 / Phase 2 · XYone Therapeutics, Inc · starts Sep 17, 2026
- A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors…NCT07630974 · Phase 1 / Phase 2 · Merck Sharp & Dohme LLC · starts Jul 6, 2026
- Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug InteractionNCT07620041 · Phase 1 · Qilu Pharmaceutical Co., Ltd. · starts Jun 9, 2026
| Nov 19, 2025 | A phase I study of GCAR1, a chimeric antigen receptor (CAR) T-cell therapy for participants with selected relapsed/refractory gpnmb-expressing solid tumoursGCAR1 / Fludarabine / Cyclophosphamide | Canadian Cancer Trials Group, Cancer Research Institute, Queen's University | Ongoing |
| Jul 14, 2025 | A phase 1/2 trial of CBL0137 (nsc# 825802, ind# 155843) in patients with relapsed or refractory solid tumors including CNS tumors and lymphomaCBL0137 | Childrens Oncology Group | Pending |
| Feb 19, 2025 | Phase I/II study of silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumorsSilmitasertib (CX-4945) | Beat Childhood Cancer Research Consortium | Ongoing |
| Mar 20, 2024 | A phase I-ii, first-in-human study of SKB264 in patients with locally advanced unresectable /metastatic solid tumors who are refractory to available standard…SKB264 (MK-2870) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd | Closed |
| Mar 11, 2022 | A phase 1/ 2 study of bay 1895344 (elimusertib, ind#152153, nsc#810486) in pediatric patients with relapsed or refractory solid tumorsElimusertib (bay 1895344) | Childrens Oncology Group | Ongoing |
| Feb 10, 2020 | Phase 1 study of the bromodomain (BRD) and extra-terminal domain (BET) inhibitor BMS-986158 in pediatric cancerBMS-986158 | Dana Farber Cancer Institute | Closed |
| Nov 23, 2018 | A phase I, multicenter dose-escalation study to assess the tolerability, pharmacokinetics and preliminary anti-tumor activity of AZD5153 in patients with…AZD5153 / Olaparib | AstraZeneca Pharmaceuticals | Closed |
| Aug 10, 2018 | A phase 1 first-in-human study with ABBV-155 alone and in combination with taxane therapy in adults with relapsed and/or refractory solid tumorsABBV-155 | AbbVie | Closed |
| Jul 6, 2017 | A phase I/II study of neratinib in pediatric patients with relapsed/ refractory solid tumorsNeratinib | Pediatric Oncology Experimental Therapeutic Investigator Consortium | Ongoing |
| Nov 13, 2014 | A phase 1/iia study of decitabine in combination with genistein in pediatric patients with relapsed or refractory solid tumors and leukemiaDecitabine / Genistein | Centre Hospitalier Universitaire Sainte-Justine | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA